Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 3, 2012, Pages 305-313

  Sellebjerg, F ^a   Hedegaard, C J ^a   Krakauer, M ^a   Hesse, D ^a   Lund, H ^b   Nielsen, C H ^a   Sondergaard H B ^a   Sorensen P S ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

antibodies; cytokines; glatiramer acetat; multiple sclerosis; transcription factors

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; LYMPHOTOXIN BETA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3;

ADULT; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; RELAPSE; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

EID: 84857857741     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511420268     Document Type: Article

References (31)

1. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005 ; 4: 567-575 (Pubitemid 41139978)
2. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010 ; 74: S25 - S30
3. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 ; 45: 1268-1276
4. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 ; 7: 903-914
5. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 ; 8: 889-897
6. Basile E, Gibbs E, Aziz T, Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol. 2006 ; 177: 161-166 (Pubitemid 44108229)
7. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol. 2001 ; 115: 152-160 (Pubitemid 32245663)
8. Farina C, Vargas V, Heydari N, Kumpfel T, Meinl E, Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol. 2002 ; 123: 188-192 (Pubitemid 34195620)
9. Karussis D, Teitelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol. 2010 ; 220: 125-130
10. Salama HH, Hong J, Zang YC, El-Mongui A, Zhang J. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain. 2003 ; 126: 2638-2647 (Pubitemid 37463083)
11. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med. 1991 ; 173: 747-750
12. Ishizaka A, Sakiyama Y, Nakanishi M, Tomizawa K, Oshika E, Kojima K, et al. The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin Exp Immunol. 1990 ; 79: 392-396 (Pubitemid 20082266)
13. Wiesemann E, Klatt J, Wenzel C, Heidenreich F, Windhagen A. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol. 2003 ; 133: 454-460 (Pubitemid 37046972)
14. Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler. 2008 ; 14: 615-621 (Pubitemid 351954403)
15. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol. 2009 ; 16: 1291-1298
16. Hesse D, Krakauer M, Lund H, Sondergaard HB, Langkilde A, Ryder LP, et al. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010 ; 74: 1455-1462
17. Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler. 2010 ;:
18. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010 ; 28: 445-489
19. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler. 2008 ; 14: 622-630 (Pubitemid 351954404)
20. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast- enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology. 1997 ; 48: 1446-1448 (Pubitemid 27240580)
21. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001 ; 49: 290-297 (Pubitemid 32202781)
22. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009 ; 72: 1976-1983
23. Farina C, Wagenpfeil S, Hohlfeld R. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study. J Neurol. 2002 ; 249: 1587-1592 (Pubitemid 35477902)
24. Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler. 2007 ; 13: 754-762 (Pubitemid 47074099)
25. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403 (Pubitemid 47511460)
26. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol. 2007 ; 14: 850-859 (Pubitemid 47106761)
27. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009 ; 73: 372-377
28. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 ; 362: 1184-1191 (Pubitemid 37255344)
29. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003 ; 9: 592-599 (Pubitemid 37479408)
30. Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J. 2002 ; 16: 1260-1262
31. Begum-Haque S, Sharma A, Christy M, Lentini T, Ochoa-Reparaz J, Fayed IF, et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 ; 219: 47-53